Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals, secures $132M PIPE, and grants $30M CVR to legacy shareholders
JSPR has more than doubled off its 52-week low of $0.315 on elevated volume (21× avg).
Summary
Jasper Therapeutics merged with Kira Pharmaceuticals in an all-stock deal, raised $132 million in a PIPE, and issued a $30 million CVR to legacy shareholders. The transaction massively dilutes existing holders but provides a pipeline and cash runway into 2H 2028.
Key Events · M&A and Partnerships · JSPR
-
Merger with Kira Pharmaceuticals
In an all-stock transaction, Jasper acquired Kira by issuing 5,195,009 common shares and 4,644,977 preferred shares—each convertible into 61 common shares, totaling 283.3 million common shares—to Kira shareholders. Post-transaction, legacy Jasper holders own approximately 6.68% of the combined company.
-
$132M Private Placement
Concurrent with the merger, Jasper sold approximately 4.7 million preferred shares—convertible into roughly 286.7 million common shares—to investors for $132 million, extending the cash runway into the second half of 2028.
-
$30M Contingent Value Right for Legacy Shareholders
Each pre-merger Jasper shareholder receives one CVR, entitling them to a pro rata share of $30 million if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028. Payment follows monetization of the voucher or a change of control.
-
Out-License to Mirador Therapeutics
Kira out-licensed KP-301 and KP-402 to Mirador for a $12 million upfront payment, plus up to $458.5 million in milestones and tiered royalties.
Analysis · JSPR · Life Sciences
The acquisition of Kira Pharmaceuticals reshapes Jasper Therapeutics, delivering a new pipeline and leadership team. To fund the combined entity, the company raised $132 million through a private placement, while legacy Jasper shareholders received a contingent value right worth up to $30 million—payable if briquilimab earns an FDA Priority Review Voucher by December 31, 2028. In a separate move, two preclinical assets were out-licensed to Mirador Therapeutics for $12 million upfront. Post-transaction, legacy Jasper holders retain just 6.68% of the fully-diluted equity, reflecting extreme dilution but securing critical capital and pipeline assets. The restructuring follows a going-concern warning and a Nasdaq delisting notice, underscoring its survival-driven nature. Governance has been overhauled: Kira's Patrick Crutcher joins the board, Matthew Ros steps in as COO, and two directors have resigned. Within 120 days, stockholders must vote to approve the conversion of preferred stock and an increase in authorized shares—a move that, if passed, will further dilute existing holders.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.7M. The 52-week trading range was $0.32 to $3.52. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.